Caribou Biosciences, Inc. experienced a 45% share price decline after presenting puzzling results for their product candidate CB-010 in a Phase 1 clinical trial. CB-010 showed limited efficacy in ...

The global HLA typing market is expected to expand at a compound annual growth rate (CAGR) of approximately 6% during the ...

Caribou Biosciences focuses on allogeneic CAR-T therapies for hematological cancers and autoimmune diseases, leveraging its unique chRDNA genome-editing technology. In my view, CRBU's chRDNA platform ...

ORLANDO -- Stem-cell transplants with mismatched unrelated donors (MMUDs) beyond a single HLA locus (<7/8) had 1-year survival similar to better-matched donors, suggesting significant potential to ...

Jayme Locke, MD MARCO ISLAND, Fla.—The transplant community may want to rethink the importance of HLA mismatches when considering live donor kidney transplants, according to new data presented here at ...

Analyses of two large stem-cell transplant registries yielded conflicting results about the effect of post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis on the ...

(ORLANDO, Dec. 6, 2025) A new study shows that giving the chemotherapy drug cyclophosphamide after allogeneic hematopoietic cell transplantation, a curative treatment for common types of blood cancer, ...

Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors The study included 17,292 unrelated ...

HLA matching in bone marrow transplantation has an important role in determining successful outcome. However HLA typing of both potential related and unrelated donors can be both time-consuming and ...

Please provide your email address to receive an email when new articles are posted on . Patients who received stem cell grafts from unrelated donors matched at as few as 4/8 HLA markers achieved ...